Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHRENILIN WITH CAFFEINE AND CODEINE vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Combination analgesic; butalbital is a barbiturate that potentiates GABA-A activity; acetaminophen inhibits cyclooxygenase (COX) and modulates cannabinoid receptors; caffeine is a nonselective adenosine receptor antagonist; codeine is a prodrug converted to morphine, a mu-opioid agonist.
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Relief of tension headache,Management of pain (off-label)
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
1-2 capsules orally every 4 hours as needed, not to exceed 8 capsules per day. Each capsule contains butalbital 50 mg, caffeine 40 mg, and codeine phosphate 30 mg.
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Butalbital: 35–50 hours; codeine: 2.5–3.5 hours; caffeine: 4–6 hours (adults), prolonged in liver disease. Clinical context: butalbital's long half-life leads to accumulation with repeated dosing; codeine's short half-life requires frequent dosing.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Butalbital: hepatic (CYP2C19); Acetaminophen: hepatic (CYP1A2, CYP2E1, conjugation); Caffeine: hepatic (CYP1A2); Codeine: hepatic via CYP2D6 to morphine; also metabolized by CYP3A4 to norcodeine.
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Renal: butalbital ~60% unchanged; codeine ~90% as metabolites (free and conjugated morphine, norcodeine); caffeine <2% unchanged, ~80% as metabolites (paraxanthine, theobromine, theophylline) via renal excretion. Biliary/fecal: minimal.
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
Butalbital: ~45% (albumin); codeine: ~7–25% (albumin); caffeine: ~10–30% (albumin).
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
Butalbital: 0.8 L/kg; codeine: 3–4 L/kg; caffeine: 0.5–0.7 L/kg. Clinical meaning: codeine's high Vd indicates extensive tissue distribution; butalbital and caffeine are more confined to extracellular water.
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
Oral: butalbital ~90%; codeine ~90% (but extensive first-pass metabolism to morphine); caffeine ~100%.
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
No specific guidelines available. Use with caution in renal impairment; consider reducing dose or extending interval. Monitor for CNS depression and constipation. For GFR < 30 m L/min, use is not recommended.
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). In mild to moderate hepatic impairment (Child-Pugh A or B), use with caution; consider reducing dose or extending interval. Monitor for excessive sedation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
Not recommended for use in children under 12 years of age. For children 12-18 years, weight-based dosing for codeine: 0.5-1 mg/kg codeine component every 4-6 hours as needed; maximum codeine dose 60 mg/dose. Butalbital and caffeine dosing not established in pediatrics; alternative therapy recommended.
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Start at the lower end of the dosing range (e.g., 1 capsule every 6 hours as needed). Monitor for increased sensitivity to CNS depressant effects, falls, confusion, and constipation. Consider reducing total daily dose. Avoid in frail elderly.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
Codeine is contraindicated in children younger than 12 years for pain relief, and contraindicated in children younger than 18 years for tonsillectomy/adenoidectomy due to risk of fatal respiratory depression.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
Risk of respiratory depression; addiction and abuse potential; acetaminophen hepatotoxicity (dose-dependent); avoid in patients with severe hepatic impairment; CYP2D6 ultra-rapid metabolizers may experience toxicity with codeine; butalbital can cause dependence and withdrawal; avoid abrupt discontinuation; may impair mental/physical abilities.
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
Hypersensitivity to any component; severe respiratory depression; acute or severe asthma; paralytic ileus; known CYP2D6 ultrarapid metabolizers; children <12 years (codeine); use after tonsillectomy/adenoidectomy in children <18 years; concurrent MAOI use or within 14 days; porphyria (butalbital).
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
Avoid grapefruit juice (may increase butalbital levels); limit or avoid caffeine-containing foods/beverages (coffee, tea, chocolate, cola) to prevent additive stimulation.
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
First trimester: Codeine (FDA Category C) and butalbital (Category C/D near term) may be associated with increased risk of congenital malformations; caffeine (Category C) at high doses may increase risk of miscarriage. Second and third trimesters: Chronic use may lead to fetal dependence, neonatal withdrawal syndrome; butalbital near term may cause neonatal bleeding due to vitamin K deficiency; codeine may cause respiratory depression if used near delivery.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
Codeine and caffeine are excreted into breast milk; butalbital is present in low levels. M/P ratio for codeine is approximately 2.0; for caffeine, ~0.5-0.7. Use with caution due to risk of infant sedation, respiratory depression, and withdrawal. Consider alternative analgesics; monitor infant for drowsiness, feeding difficulties, or apnea.
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
Pregnancy can alter pharmacokinetics: increased blood volume, renal clearance, and hepatic metabolism may reduce drug concentrations. Codeine: increased clearance may require dose adjustment; observe for efficacy. Butalbital: limited data; increased metabolism possible. Caffeine: clearance decreases in later pregnancy; avoid high doses. Individualize dosing based on clinical response and avoid fixed-dose combinations if possible.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
Monitor respiratory depression risk, especially in elderly or COPD patients; avoid concurrent use with other CNS depressants; assess liver function due to butalbital metabolism; caffeine may exacerbate anxiety or insomnia.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
Do not exceed prescribed dose; may cause drowsiness, avoid driving or operating machinery.,Avoid alcohol and other sedatives; risk of severe drowsiness or breathing problems.,Store securely; risk of abuse and dependence; do not share with others.,Report symptoms of withdrawal (e.g., anxiety, insomnia) when discontinuing.,Caffeine content may cause jitteriness, palpitations, or sleep disturbances.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHRENILIN WITH CAFFEINE AND CODEINE vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE, answered by our medical review team.
PHRENILIN WITH CAFFEINE AND CODEINE is a Opioid Agonist that works by Combination analgesic; butalbital is a barbiturate that potentiates GABA-A activity; acetaminophen inhibits cyclooxygenase (COX) and modulates cannabinoid receptors; caffeine is a nonselective adenosine receptor antagonist; codeine is a prodrug converted to morphine, a mu-opioid agonist.. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHRENILIN WITH CAFFEINE AND CODEINE and ACETAMINOPHEN AND HYDROCODONE BITARTRATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHRENILIN WITH CAFFEINE AND CODEINE is: 1-2 capsules orally every 4 hours as needed, not to exceed 8 capsules per day. Each capsule contains butalbital 50 mg, caffeine 40 mg, and codeine phosphate 30 mg.. The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining PHRENILIN WITH CAFFEINE AND CODEINE and ACETAMINOPHEN AND HYDROCODONE BITARTRATE. Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Codeine. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. PHRENILIN WITH CAFFEINE AND CODEINE is classified as Category D/X. First trimester: Codeine (FDA Category C) and butalbital (Category C/D near term) may be associated with increased risk of congenital malformations; caffeine (Category C) at high d. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.